interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Glucagon

Generic competition · all medicines · read 12 November 2026

Is there a generic of Glucagon, and who makes it?

Glucagon appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 4 generic makers listed as marketed across them. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 22.3 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Glucagon4 dosage-form groups in the Orange Book
4generic makers listed
  1. Glucagon appears in 4 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 4 generic makers listed as marketed across them.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 22.3 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Injectable, Injection

Four or more generic makers listed

Every brand product here is listed as discontinued. 4 generic makers with 4 generic products listed as marketed; the first generic approval is dated 28 December 2020.

1995200020052010201520202025203004brand 1998Amphastar Pharmaceuticals Inc, first approval 28 December 2020Mylan Laboratories Ltd, first approval 12 December 2024Lupin Ltd, first approval 22 July 2025Cipla Ltd, first approval 15 September 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Amphastar Pharmaceuticals Inc28 December 20201
Mylan Laboratories Ltd12 December 20241
Lupin Ltd22 July 20251
Cipla Ltd15 September 20251

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Gvoke Hypopen, Gvoke Kit and Gvoke Pfs. No generic is listed as marketed.

20152020202520302035204001brand 2019data datePatent 9649364 listed to expire 22 April 2036Patent 11590205 listed to expire 22 April 2036
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 22 April 2036Patent 9649364 drug product
  • 22 April 2036Patent 11590205 drug product

Powder, Nasal

Brand listed, no generic listed as marketed

Brand listed as marketed: Baqsimi. No generic is listed as marketed.

20152020202520302035204001brand 2019data datePatent 10213487 listed to expire 16 February 2036Patent 12370241 listed to expire 16 February 2036Patent 10765602 listed to expire 23 September 2039Exclusivity NPP to 17 March 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 17 March 2028Exclusivity NPP Baqsimi
  • 16 February 2036Patent 10213487 drug product
  • 16 February 2036Patent 12370241 drug product
  • 23 September 2039Patent 10765602 drug product

Solution, Intravenous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

20202025203001brand 2025data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.